Logo
x

Search

Subscribe Now

Remitting

Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis

Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis

  • August 3, 2020
BMS's Zeposia (ozanimod) Receives the CHMP's Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Active Disease

BMS's Zeposia (ozanimod) Receives the CHMP's Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Act...

  • March 30, 2020
Biogen

    Biogen's Plegridy (peginterferon beta-1a- IM) Receives EC's Approval for Relapsing-Remitting MS

    • December 22, 2020
    BMS

      BMS' Zeposia (ozanimod) Receives Health Canada Approval for Relapsing Remitting Multiple Sclerosis

      • October 8, 2020
      Roche to Present New Data of Ocrevus (ocrelizumab) for Relapsing-Remitting Multiple Sclerosis at MSVirtual2020

        Roche to Present New Data of Ocrevus (ocrelizumab) for Relapsing-Remitting Multiple Sclerosis at MSVirtual2020

        • September 11, 2020
        Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis

          Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis

          • August 3, 2020
          BMS

            BMS's Zeposia (ozanimod) Receives the CHMP's Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Act...

            • March 30, 2020
            Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relapsing-Remitting Multiple Sclerosis

              Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relaps...

              • September 3, 2019
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.